Maria Caterina Turco

List of Publications by Year
in descending order

119	4,035	117453	128067
papers	citations	34 h-index	60 g-index

121	121	121	4966
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration. Journal of Cellular Biochemistry, 2022, 123, 65-76.	1.2	6
2	BAG3 induces Î±â€SMA expression in human fibroblasts and its overâ€expression correlates with poorer survival in fibrotic cancer patients. Journal of Cellular Biochemistry, 2022, 123, 91-101.	1.2	4
3	The coâ€chaperone BAG3: Orchestrator of the cellular task force in response to stress. Journal of Cellular Biochemistry, 2022, 123, 3-3.	1.2	0
4	Concerted BAG3 and SIRPÎ± blockade impairs pancreatic tumor growth. Cell Death Discovery, 2022, 8, 94.	2.0	2
5	Proteomics Approach Highlights Early Changes in Human Fibroblasts-Pancreatic Ductal Adenocarcinoma Cells Crosstalk. Cells, 2022, 11, 1160.	1.8	4
6	An emerging role for BAG3 in gynaecological malignancies. British Journal of Cancer, 2021, 125, 789-797.	2.9	10
7	What's in the BAGs? Intrinsic disorder angle of the multifunctionality of the members of a family of chaperone regulators. Journal of Cellular Biochemistry, 2021, , .	1.2	3
8	Iodine intake among children: Letter. Journal of Trace Elements in Medicine and Biology, 2020, 62, 126610.	1.5	0
9	Comment on: â€˜Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patientsâ€™. British Journal of Cancer, 2020, 123, 1467-1467.	2.9	0
10	BAG3 in Tumor Resistance to Therapy. Trends in Cancer, 2020, 6, 985-988.	3.8	12
11	Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. Pathology Research and Practice, 2020, 216, 153025.	1.0	30
12	The multiple activities of BAG3 protein: Mechanisms. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129628.	1.1	24
13	Development of an antiâ€BAG3 humanized antibody for treatment of pancreatic cancer. Molecular Oncology, 2019, 13, 1388-1399.	2.1	18
14	CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMsâ€“Letter. Clinical Cancer Research, 2019, 25, 892-893.	3.2	10
15	Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8 ⁺ T cell number and tumour growth in pancreatic cancer. Gut, 2018, 67, gutjnl-2017-314225.	6.1	33
16	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. Journal of Cellular Physiology, 2018, 233, 1791-1795.	2.0	6
17	Role of BAG3 in cancer progression: A therapeutic opportunity. Seminars in Cell and Developmental Biology, 2018, 78, 85-92.	2.3	61
18	Microbiota effects on cancer: from risks to therapies. Oncotarget, 2018, 9, 17915-17927.	0.8	155

#	Article	IF	Citations
19	Chaperone-assisted selective autophagy in healthy and papillomavirus-associated neoplastic urothelium of cattle. Veterinary Microbiology, 2018, 221, 134-142.	0.8	11
20	Discovery and synthesis of the first selective BAG domain modulator of BAG3 as an attractive candidate for the development of a new class of chemotherapeutics. Chemical Communications, 2018, 54, 7613-7616.	2.2	13
21	Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis. Oncotarget, 2018, 9, 8016-8026.	0.8	4
22	BAG3 Protein Is Overâ€Expressed in Endometrioid Endometrial Adenocarcinomas. Journal of Cellular Physiology, 2017, 232, 309-311.	2.0	16
23	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. Oncotarget, 2017, 8, 80393-80404.	0.8	16
24	The prosurvival protein BAG3: a new participant in vascular homeostasis. Cell Death and Disease, 2016, 7, e2431-e2431.	2.7	15
25	BAG3 regulates formation of the SNARE complex and insulin secretion. Cell Death and Disease, 2015, 6, e1684-e1684.	2.7	19
26	Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. Clinica Chimica Acta, 2015, 445, 73-78.	0.5	17
27	BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nature Communications, 2015, 6, 8695.	5.8	81
28	A novel miR-371a-5p-mediated pathway, leading to BAG3 upregulation in cardiomyocytes in response to epinephrine, is lost in Takotsubo cardiomyopathy. Cell Death and Disease, 2015, 6, e1948-e1948.	2.7	35
29	WW Domain of BAG3 Is Required for the Induction of Autophagy in Glioma Cells. Journal of Cellular Physiology, 2015, 230, 831-841.	2.0	45
30	BAG3 protein expression in melanoma metastatic lymph nodes correlates with patientsâ€™ survival. Cell Death and Disease, 2014, 5, e1173-e1173.	2.7	18
31	BAG3 Protein in Advanced-Stage Heart Failure. JACC: Heart Failure, 2014, 2, 673-675.	1.9	15
32	Design, structural and biological characterization of a VEGF inhibitor Î²-hairpin-constrained peptide. European Journal of Medicinal Chemistry, 2014, 73, 210-216.	2.6	21
33	The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth. Oncotarget, 2014, 5, 6846-6853.	0.8	27
34	Therapeutic potential of a pyridoxalâ€based vanadium(IV) complex showing selective cytotoxicity for cancer versus healthy cells. Journal of Cellular Physiology, 2013, 228, 2202-2209.	2.0	46
35	Polymorphisms of the antiapoptotic protein bag3 may play a role in the pathogenesis of tako-tsubo cardiomyopathy. International Journal of Cardiology, 2013, 168, 1663-1665.	0.8	27
36	Role of WT1â€“ZNF224 interaction in the expression of apoptosis-regulating genes. Human Molecular Genetics, 2013, 22, 1771-1782.	1.4	20

#	Article	IF	Citations
37	Detection of soluble BAG3 and anti-BAG3 antibodies in patients with chronic heart failure. Cell Death and Disease, 2013, 4, e495-e495.	2.7	26
38	BAG3 Is a Novel Serum Biomarker for Pancreatic Adenocarcinomas. American Journal of Gastroenterology, 2013, 108, 1178-1180.	0.2	30
39	Expression of the Anti-Apoptotic Protein BAG3 in Human Melanomas. Journal of Investigative Dermatology, 2012, 132, 252-254.	0.3	20
40	BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E115-E120.	1.8	28
41	BAG3 controls angiogenesis through regulation of ERK phosphorylation. Oncogene, 2012, 31, 5153-5161.	2.6	39
42	Scouting new molecular targets for CFTR therapy: the HSC70/BAG-1 complex. A computational study. Medicinal Chemistry Research, 2012, 21, 4430-4436.	1.1	2
43	Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 407-414.	3.3	6
44	Expression of the Antiapoptotic Protein BAG3 Is a Feature of Pancreatic Adenocarcinoma and Its Overexpression Is Associated With Poorer Survival. American Journal of Pathology, 2012, 181, 1524-1529.	1.9	53
45	Matrine modulates HSC70 levels and rescues Î”F508â€CFTR. Journal of Cellular Physiology, 2012, 227, 3317-3323.	2.0	14
46	Role of BAG3 protein in leukemia cell survival and response to therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 365-369.	3.3	22
47	Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochemical Pharmacology, 2012, 84, 303-311.	2.0	88
48	Bag3-Induced Autophagy Is Associated with Degradation of JCV Oncoprotein, T-Ag. PLoS ONE, 2012, 7, e45000.	1.1	34
49	Characterization of a Designed Vascular Endothelial Growth Factor Receptor Antagonist Helical Peptide with Antiangiogenic Activity in Vivo. Journal of Medicinal Chemistry, 2011, 54, 1391-1400.	2.9	40
50	BAG3 Protein Is Overexpressed in Human Glioblastoma and Is a Potential Target for Therapy. American Journal of Pathology, 2011, 178, 2504-2512.	1.9	111
51	Î²-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (VEGF) Receptors. Journal of Biological Chemistry, 2011, 286, 41680-41691.	1.6	32
52	Exposure to 50â€‰Hz electromagnetic field raises the levels of the antiâ€apoptotic protein BAG3 in melanoma cells. Journal of Cellular Physiology, 2011, 226, 2901-2907.	2.0	25
53	The expression of the proâ€apoptotic gene Air is inducible in human pancreatic adenocarcinoma cells. Journal of Cellular Physiology, 2011, 226, 2207-2212.	2.0	4
54	BAG3 is required for IKKÎ± nuclear translocation and emergence of castration resistant prostate cancer. Cell Death and Disease, 2011, 2, e139-e139.	2.7	15

#	Article	IF	Citations
55	BAG3: a multifaceted protein that regulates major cell pathways. Cell Death and Disease, 2011, 2, e141-e141.	2.7	266
56	BAG3 protein is induced during cardiomyoblast differentiation and modulates myogenin expression. Cell Cycle, 2011, 10, 850-852.	1.3	14
57	BAG3 Protein: Role in Some Neoplastic Cell Types and Identification as a Candidate Target for Therapy. , 2010, , 137-146.		3
58	BAG3 protein delocalisation in prostate carcinoma. Tumor Biology, 2010, 31, 461-469.	0.8	34
59	Ferritin Heavy Chain (FHC) is Up-regulated in Papillomavirus-Associated Urothelial Tumours of the Urinary Bladder in Cattle. Journal of Comparative Pathology, 2010, 142, 9-18.	0.1	12
60	WT1 protein is a transcriptional activator of the antiapoptotic bag3 gene. Leukemia, 2010, 24, 1204-1206.	3.3	31
61	IKKÎ³ protein is a target of BAG3 regulatory activity in human tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7497-7502.	3.3	101
62	Review of Molecular Mechanisms Involved in the Activation of the Nrf2-ARE Signaling Pathway by Chemopreventive Agents. Methods in Molecular Biology, 2010, 647, 37-74.	0.4	210
63	The co-chaperone BAG3 interacts with the cytosolic chaperonin CCT: New hints for actin folding. International Journal of Biochemistry and Cell Biology, 2010, 42, 641-650.	1.2	44
64	Evidence for modulation of BAG3 by polyomavirus JC early protein. Journal of General Virology, 2009, 90, 1629-1640.	1.3	17
65	Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2009, 3, 80-86.	0.7	0
66	Physiology of Immune System: Regulation of Stem Cell Survival. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2009, 3, 35-41.	0.7	0
67	BAG3 protein regulates caspaseâ€3 activation in HIVâ€1â€infected human primary microglial cells. Journal of Cellular Physiology, 2009, 218, 264-267.	2.0	35
68	Identification of a Btkâ€“BAG3 complex induced by oxidative stress. Leukemia, 2009, 23, 823-824.	3.3	14
69	The activity of hsp90Î± promoter is regulated by NF-ÎºB transcription factors. Oncogene, 2008, 27, 1175-1178.	2.6	68
70	Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells. Oncogene, 2008, 27, 5011-5018.	2.6	40
71	bag3 gene expression is regulated by heat shock factor 1. Journal of Cellular Physiology, 2008, 215, 575-577.	2.0	103
72	Identification of a synaptosome- associated form of BAG3 protein. Cell Cycle, 2008, 7, 3104-3105.	1.3	20

#	Article	IF	Citations
73	The Antiapoptotic Protein BAG3 Is Expressed in Thyroid Carcinomas and Modulates Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1159-1163.	1.8	99
74	Apoptosis inhibition in cancer cells: A novel molecular pathway that involves BAG3 protein. International Journal of Biochemistry and Cell Biology, 2007, 39, 1337-1342.	1.2	126
75	Antiproliferative and pro-apoptotic activity of novel phenolic derivatives of resveratrol. Life Sciences, 2007, 81, 873-883.	2.0	19
76	Evidence for BAG3 modulation of HIV-1 gene transcription. Journal of Cellular Physiology, 2007, 210, 676-683.	2.0	65
77	Modulation of cell apoptosis by AIR. Leukemia, 2007, 21, 2557-2559.	3.3	1
78	1-Methoxy-Canthin-6-One Induces c-Jun NH2-Terminal Kinaseâ€“Dependent Apoptosis and Synergizes with Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand Activity in Human Neoplastic Cells of Hematopoietic or Endodermal Origin. Cancer Research, 2006, 66, 4385-4393.	0.4	35
79	The Antiâ€“Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. Cancer Research, 2006, 66, 1799-1808.	0.4	37
80	NF-ÎºB protects BehÃ§et's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis and Rheumatism, 2005, 52, 2179-2191.	6.7	59
81	Activation of NF-ÎºB/Rel transcription factors in human primary peripheral blood mononuclear cells by interleukin 7. Biological Chemistry, 2004, 385, 415-417.	1.2	4
82	Quassinoids can induce mitochondrial membrane depolarisation and caspase 3 activation in human cells. Cell Death and Differentiation, 2004, 11, S216-S218.	5.0	34
83	NF-ÎºB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia, 2004, 18, 11-17.	3.3	84
84	BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia, 2004, 18, 358-360.	3.3	86
85	Nuclear Factor-ÎºB Regulates Inflammatory Cell Apoptosis and Phagocytosis in Rat Carrageenin-Sponge Implant Model. American Journal of Pathology, 2004, 165, 115-126.	1.9	33
86	BAG3 protein controls B-chronic lymphocytic leukaemia cell apoptosis. Cell Death and Differentiation, 2003, 10, 383-385.	5.0	103
87	Effect of NF-ÎºB/Rel inhibition on spontaneous vs chemotherapy-induced apoptosis in AML and normal cord blood CD34+ cells. Leukemia, 2003, 17, 1190-1192.	3.3	12
88	BAG3 Protein Regulates Cell Survival in Childhood Acute Lymphoblastic Leukemia Cells. Cancer Biology and Therapy, 2003, 2, 508-510.	1.5	65
89	High-mobility group A1 proteins are overexpressed in human leukaemias. Biochemical Journal, 2003, 372, 145-150.	1.7	39
90	Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. European Journal of Cancer, 2002, 38, 1141-1147.	1.3	11

#	Article	IF	Citations
91	Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends in Neurosciences, 2001, 24, 411-416.	4.2	185
92	HLA class I antigen downregulation by interleukin (IL)-10 is predominantly governed by NF-kappaB in the short term and by TAP1+2 in the long term. Tissue Antigens, 2000, 55, 326-332.	1.0	14
93	Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death and Differentiation, 2000, 7, 327-328.	5.0	31
94	Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia, 2000, 14, 841-844.	3.3	133
95	CD40 and B Chronic Lymphocytic Leukemia Cell Response To Fludarabine: The Influence of NF-kB/Rel Transcription Factors On Chemotherapy-Induced Apoptosis. Leukemia and Lymphoma, 2000, 36, 255-262.	0.6	12
96	Increased Expression of CD40 Ligand in Activated CD4+T Lymphocytes of Systemic Sclerosis Patients. Journal of Autoimmunity, 2000, 15, 61-66.	3.0	44
97	Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-ÎºB/Rel Transcription Factors. Blood, 1999, 94, 4060-4066.	0.6	54
98	Regulation of cell survival in CD95-induced T cell apoptosis: role of NF-kappa B/Rel transcription factors. Apoptosis: an International Journal on Programmed Cell Death, 1999, 4, 179-186.	2.2	4
99	Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-ÎºB/Rel Transcription Factors. Blood, 1999, 94, 4060-4066.	0.6	2
100	CD36 is rapidly and transiently upregulated on phytohemagglutinin (PHA)â€stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7). Tissue Antigens, 1998, 51, 671-675.	1.0	4
101	Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. Blood, 1998, 92, 990-995.	0.6	127
102	Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. Blood, 1998, 92, 990-995.	0.6	8
103	Induction of nuclear factor kB/Rel nuclear activity in human peripheral blood T lymphocytes by antiâ€HLA class I monoclonal antibodies. Tissue Antigens, 1997, 50, 1-7.	1.0	9
104	CD69 expression on primitive progenitor cells and hematopoietic malignancies. Tissue Antigens, 1996, 48, 65-68.	1.0	7
105	Detection of an antigenic marker expressed by peripheral blood monocytes and platelets by a new monoclonal antibody UN8. Tissue Antigens, 1995, 45, 288-291.	1.0	0
106	Analysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2. Immunology Letters, 1994, 42, 55-62.	1.1	1
107	A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells. Immunology Letters, 1994, 39, 137-146.	1.1	2
108	Regulation of NF-ÎºB Nuclear Activity in Peripheral Blood Mononuclear Cells: Role of CD28 Antigen. Cellular Immunology, 1994, 156, 371-377.	1.4	7

#	Article	IF	Citations
109	UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. Tissue Antigens, 1994, 44, 73-82.	1.0	13
110	Defect of Interleukin-2 Production and T Cell Proliferation in Atopic Patients: Restoring Ability of the CD28-Mediated Activation Pathway. Cellular Immunology, 1993, 148, 455-463.	1.4	5
111	UN-1, a murine monoclonal antibody recognizing a human thymocyte undescribed antigen. Pharmacological Research, 1992, 26, 128-129.	3.1	1
112	Defect of CD2- and CD3-mediated activation pathways in T cells of atopic patients: Role of interleukin 2. Cellular Immunology, 1992, 139, 91-97.	1.4	6
113	Identification and characterization of a T cell growth inhibitory factor produced by K562 erythromyeloid cells. Cellular Immunology, 1991, 138, 55-63.	1.4	1
114	Mitogenic activity of antiâ€CD28 MoAb CLBâ€CD28/1 on peripheral blood mononuclear cells and its cooperation with other antiâ€T cells MoAb in the activation of purified T lymphocytes. Tissue Antigens, 1990, 36, 12-18.	1.0	4
115	Inhibition by anti-HLA class I mAb of IL-2 and IL-2 receptor synthesis in lymphocytes stimulated with PHA-P. Cellular Immunology, 1990, 126, 420-427.	1.4	10
116	Lack of a role of monocytes in the inhibition by monoclonal antibodies to monomorphic and polymorphic determinants of HLA class I antigens of PHA-P-induced peripheral blood mononuclear cell proliferation. Cellular Immunology, 1989, 122, 164-177.	1.4	9
117	Lymphocyte proliferative response to mitogenic monoclonal antibodies in systemic sclerosis. Evidence for unresponsiveness to murine monoclonal antibodies of IgG1 isotype. Tissue Antigens, 1989, 33, 457-465.	1.0	1
118	Proliferative pathways in CD1- CD3+ CD4+ CD8+ T-prolymphocytic leukemic cells: analysis with monoclonal antibodies and cytokines. Blood, 1989, 74, 1651-1657.	0.6	0
119	Heterogeneity in the mitogenic response of peripheral blood mononuclear cells to a pan T monoclonal antibody. Tissue Antigens, 1988, 31, 59-68.	1.0	4